SUNPHARMA

Sun Pharmaceutical Industries Ltd is India’s largest pharma company and among the top global generic drug manufacturers. It sells medicines in 100+ countries with strong presence in India, US, and emerging markets. Key business segments: Generic medicines Specialty drugs (dermatology, oncology etc.) Active pharmaceutical ingredients (API) Fundamental View Strengths Strong revenue growth and global presence. FY24 revenue around ₹49,505 crore and profit ₹9,602 crore. EBITDA margins close to 27-30%. High R&D spending (6-7% of revenue) for specialty drugs. Support ₹1600 ₹1550 – ₹1528 zone Resistance ₹1700 ₹1750 – ₹1780 breakout zone. 📌 If breakout above ₹1750–1780, possible rally toward ₹1950–2000. 📌 If breakdown below ₹1600, downside may extend toward ₹1540–1500.